<DOC>
	<DOC>NCT00750555</DOC>
	<brief_summary>Phase II Study of Maintenance Tarceva (Erlotinib) in patients with locally advanced Head and Neck Cancer after treatment with curative intent</brief_summary>
	<brief_title>Maintenance of Tarceva (Erlotinib) in Patients With Locally Advanced Head and Neck Cancer</brief_title>
	<detailed_description />
	<mesh_term>Head and Neck Neoplasms</mesh_term>
	<mesh_term>Erlotinib Hydrochloride</mesh_term>
	<criteria>Stage III, IV SCCHN Completed curative treatment Prior chemotherapy or radiotherapy Recurrent disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2012</verification_date>
	<keyword>squamous cell cancer of head and neck</keyword>
	<keyword>SCCHN</keyword>
</DOC>